Vinorelbine as a monotherapy in metastatic breast cancer treatment

Aim: to analyze the results of treatment with vinorelbine in patients with metastatic breast cancer (BC). Patients and methods: There were 5943 of new cases of BC in Moscow and there were 2378 patients with IV stage of the disease. 113 patients were treated with vinorelbine as a monotherapy, 1056 had other options of chemotherapy and 1209 patients had no treatment. As a first-line therapy vinorelbine was used in 13.5% of patients, as a second-line – in 59.7% and as a third-line – in 26.8%. Results: There were no significant difference in 1-year survival between group of treatment with vinorelbine (CI 95%; 0.25–1.0), group of other options of chemotherapy (CI 95%; 0.47–1.0) and group with no treatment (CI 95%; 0.32–0.49). But there were a clear tendency of increasing of difference between vinorelbine group and group without treatment. Conclusion: Vinorelbine is an ef fective and well-tolerated agent in patients with metastatic BC. But randomized multicenter trials are needed to evaluate ef ficacy of vinorelbine as a monotherapy.